# First Line Metastatic Breast Cancer Treatment (ESMERALDA)

> **NCT01941407** · PHASE2 · COMPLETED · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 61 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Eribulin

## Key facts

- **NCT ID:** NCT01941407
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-08
- **Final completion:** 2016-03
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2016-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01941407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01941407, "First Line Metastatic Breast Cancer Treatment (ESMERALDA)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01941407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*